Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001628280-25-027698
Filing Date
2025-05-27
Accepted
2025-05-27 07:01:17
Documents
1

Document Format Files

Seq Description Document Type Size
1 DEFA14A defa14a-proxysupplement2025.htm DEFA14A 31350
  Complete submission text file 0001628280-25-027698.txt   32398
Mailing Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037
Business Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037 202-734-3400
Vanda Pharmaceuticals Inc. (Filer) CIK: 0001347178 (see all company filings)

EIN.: 030491827 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-34186 | Film No.: 25984165
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)